COMPOSITION BASED ON SALTS OF HYALURONIC ACID FOR TREATING EPITHELIAL LESIONS

Abstract

Compositions based on physiologically acceptable salts of hyaluronic acid having very low viscosity, usable for the treatment and prevention of epithelial lesions and lesions of the connective tissue.

Description

DETAILED DESCRIPTION OF THE INVENTION

Some non-limiting examples are described hereinafter to clarify the understanding of the present invention.

EXAMPLE 1

In accordance with the procedure described in Example 1 of U.S. Pat. No. 5,093,487, the sodium salt of hyaluronic acid is prepared having an average molecular weight of 1,800,000 and a viscosity of 9 mPa·s at a concentration of 1% w/v in water at 20° C.

This salt can be used at a concentration of 0.005% to prepare a composition for treating lesions of the vaginal and oral epithelium.

EXAMPLE 2

Again in accordance with the teachings of Example 1 of U.S. Pat. No. 5,093,487, the sodium salt of hyaluronic acid is prepared having an average molecular weight of 1,000,000 and a viscosity of 5 mPa·s at a concentration of 1% w/v in water at 20° C.

The salt obtained can be used to prepare a composition (in which the hyaluronic acid sodium salt has a concentration of 5%) which can be solid, or in the form of tablets to be swallowed, or of the type commonly known as chewing gum.

This composition can be used to treat lesions of the oral, pharyngeal and esophageal cavity.

EXAMPLE 3

Using the method described in U.S. Pat. No. 4,517,295, hyaluronic acid as sodium hyaluronate is prepared having an average molecular weight of 10,000 and a viscosity of 1.5 mPa·s at a concentration of 6% w/v in water at 20° C. The compound obtained is used to prepare an injectable liquid composition (in which the compound is present in a concentration of 10%), in particular for treating internal traumatic and surgical lesions and for treating ocular lesions and lesions of the auditory duct. A compound of the aforedescribed type is marketed by the French company SOLIANCE with the symbol HA TBPM.

EXAMPLE 4

Again in accordance with the teachings of U.S. Pat. No. 4,517,295, hyaluronic acid as sodium hyaluronate is prepared having an average molecular weight of 27,000 and a viscosity of 0.5 mPa·s at a concentration of 2% w/v in water at 20° C.

This product can be used to prepare powders (consisting of 100% of the product) usable in odontostomatology, for example after dental extractions.

A product with the aforestated characteristics is produced by the French company SOLIANCE with the name Renovhyal.

EXAMPLE 5

Using the same method as Examples 3 and 4, hyaluronic acid as sodium hyaluronate is prepared having an average molecular weight of 50,000 and a viscosity of 4 mPa·s at a concentration of 5% w/v in water at 20° C.

This product can be used to prepare a cream or gel (in which the product is present in a concentration of 1%) for treating lesions of the cutis or of the mucosa (anal, vaginal).

This product is also available from the French company SOLIANCE, again with the brand name Renovhyal.

Claims

1. Compositions for treating lesions of the epithelium and of the connective tissue, containing between 0.001% and 100% of at least one physiologically acceptable salt of hyaluronic acid, and having a viscosity of 0 (zero) mPa·s at a concentration of 1% w/v in water at 20° C. and less than 10 mPa·s at a concentration of 6% w/v in water at 20° C.

2. Compositions according to claim 1, wherein said physiologically acceptable salts of are selected from the group consisting of sodium and potassium salts of hyaluronic acid.

3. Compositions as claimed in claims 1 and 2, characterized by comprising excipients compatible with hyaluronic acid and with their use in treating the indicated lesions.

4. Use of physiologically acceptable salts of hyaluronic acid having a viscosity of 0 (zero) mPa·s at a concentration of 1% w/v in water at 20° C. and less than 10 mPa·s at a concentration of 6% w/v in water at 20° C. to prepare pharmaceutical compositions for treating lesions of the epithelium and of the connective tissue.

5. Method for treating lesions of the epithelium and of the connective tissue which comprises administering to the patients offering of said lesions a composition according to any of claims 1, 2 or 3.